Circulating tumor DNA (ctDNA) mutations may predict treatment response in extensive-stage small cell lung cancer (ES-SCLC) treated with talazoparib and temozolomide (TMZ). Matthew C. Mulroy,Amy Lauren Cummings, Melody A. Mendenhall,David E. Kanamori,Andrew V. Nguyen,David Dae-Young Kim, William E. Lawler, Tirrell T. Johnson, Jennifer Tseng,Sunil Babu,Andrew Bennett Brown,Shaker R. Dakhil,Sidharth Anand,Zev A. Wainberg,Dennis J. Slamon,Edward B. Garon,Jonathan Wade GoldmanJOURNAL OF CLINICAL ONCOLOGY(2021)引用 2|浏览0暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要